

Case report

Clinical application of dapsone in two cases of canine sterile nodular panniculitis

Sun-Hwa Kim, Sun-Hyung Cho, Ji-Houn Kang, Mhan-Pyo Yang, In-Pil Mo, Byeong-Teck Kang*

Veterinary Teaching Hospital, College of Veterinary Medicine, Chungbuk National University

This report describes the different responses to dapsone treatment in two cases of sterile nodular panniculitis (SNP). Two dogs were presented with ulcerative skin lesions, painful and erythematous papules, and nodules. History and physical examination revealed systemic signs such as pyrexia, lethargy, depression, and anorexia, in addition to ulcerated and ruptured nodules on the skin. The dermatological diagnostics included clear taping, trichogram, skin scraping, impression smears, fungal and bacterial cultures, and histopathology and special stainings of multiple punch biopsies obtained from the skin lesions. Based on the clinical and histopathologic findings, the absence of microbiological infection, and the positive response to immunosuppressive therapy, both the dogs were diagnosed with SNP. Although both dogs had been treated with various immunosuppressive drugs including prednisolone, cyclosporine, azathioprine, and triamcinolone, therapy was switched to dapsone due to recurrent dermatological signs and presumed steroid-induced hepatotoxicity. The clinical responses to dapsone were opposite in the two cases. In the first case, combination therapy with prednisolone and cyclosporine was effective in attenuating ulcerative lesions, while dapsone alone did not control the clinical signs. In contrast, in the second case, the therapeutic response to the common immunomodulatory drugs such as prednisolone, triamcinolone, and azathioprine was inadequate. Interestingly, dapsone alone was effective in controlling the clinical signs without causing undue side effects. Although the usefulness of dapsone for the treatment of canine SNP is unknown, it may be considered in mild to moderate cases of SNP when the use of steroids is not recommended due to its low efficacy or side effects.

Key words: dapsone, dog, histopathology, skin, sterile nodular panniculitis

Introduction

Panniculitis is a skin disease characterized by inflammation of the subcutaneous fat tissues [1]. Sterile nodular panniculitis (SNP) appears as a single or multiple deep-seated nodules of varying sizes [2]. The skin lesions often become fistulated and drain an oily substance [2-4]. Additionally, systemic signs including a fever, inappetence, and lethargy wax and wane along with the skin changes [4].

In cases of SNP, histopathology reveals pyogranulomatous or granulomatous inflammation originating in the subcutis rather than the dermis [5]. SNP may progress to a more diffuse pattern with necrosis and fistulous tracts extending into the dermis and epidermis [6]. A diagnosis of SNP can be made after ruling out infectious and other noninfectious causes [1].

Dapsone, also known as diaminodiphenyl sulfone, has a combination of antimicrobial, antiprotozoal, and anti-inflammatory effects [7]. It has been used in the treatment of various immune-mediated dermatoses, such as pemphigus complex [8, 9], vasculitis [10, 11], and neutrophilic dermatitis [12, 13]. SNP is treated with immunomodulatory drugs including prednisolone, azathioprine, and cyclosporine [2], while the usefulness of dapsone is yet unknown. This report describes the clinical application of dapsone in two cases of SNP.

Case Report

A 12-year-old, neutered male, Maltese dog was presented to the Veterinary Medical Center (VMC) of Chungbuk National University for generalized ulcerative dermatitis. Two years ago, the skin lesions began as papules in the perianal area. Intermittently, the dog was treated with steroids over an 18-month period, but the clinical

*Corresponding author: Byeong-Teck Kang,

College of Veterinary Medicine, Chungbuk National University, Cheongju 28644, Korea
Tel: +82-43-261-3744, Fax: +82-43-267-2595, E-mail: kangbt@chungbuk.ac.kr

symptoms recurred repeatedly.

Two months prior to presentation, skin lesions developed on the head, which then progressed to crusts and multifocal ulcers. These lesions spread to the trunk, dorsum, limbs, gluteal region, and abdomen within 2 days. The dog also developed systemic signs including pyrexia, lethargy, and anorexia. Because there was no clinical response to antibacterial and antifungal drugs, the dog was treated with leflunomide at the local hospital. With this treatment, the clinical symptoms improved but was not resolved completely.

On presentation to the VMC, dermatological examination revealed multifocal alopecia, erythema, ulcers, and crusts on the trunk, dorsum, limbs, gluteal region, and abdomen (Fig. 1A). Depression and anorexia were also noted.

A hematological analysis revealed moderate anemia (packed cell volume: 21.5%, reference range: 37.3-

61.7%) and severe neutrophilic leukocytosis (white blood cell count: 40,770/ μ L, reference range: 5,050-16,760/ μ L; neutrophils: 35,918/ μ L, reference range: 2,950-11,640/ μ L). Hypoalbuminemia (albumin: 1.5 g/dL, reference range: 2.6-3.3 g/dL) and increased alkaline phosphatase (ALP) level (1,375 IU/L, reference range: 29-97 IU/L) were noted on the serum chemistry panel.

Impression smears obtained from the ulcerative skin lesions demonstrated numerous degenerate neutrophils, macrophages, and a few acantholytic cells. No etiological agents were observed on the clear taping, trichogram, skin scraping, and cultures for bacteria and fungi. Initially, amoxicillin-clavulanic acid (25 mg/kg, PO, twice daily; Clavamox, Zoetis, Korea), itraconazole (5 mg/kg, PO, once daily; Sponazol, Hankook Nelson Pharm, Korea), and ivermectin (300 μ g/kg, PO, once daily; Ivo-mec, Merial, Brazil) were prescribed for 7 days. Because skin lesions were inflamed, multiple punch biopsies were




Fig. 1. Temporal changes of skin lesions in the right lateral and dorsal views in case 1. (A) On presentation, erythematous and ulcerative plaques were noted on the dorsum and flank. (B) After 113 days of therapy with prednisolone (PDS) and cyclosporine, the ulcerative lesions had disappeared. (C) Erythematous nodules recurred 28 days after stopping the treatment. (D) No clinical response was noted after 6 days of treatment with dapsone. (E) The skin lesions were greatly improved 8 days after reinstatement of therapy with PDS and cyclosporine.

obtained from the trunk. Histopathology revealed pyogranulomatous nodular to diffuse dermatitis, hyperplasia, and hypertrophy of the dermis, and panniculus adiposus (Fig. 2). The inflammatory cells were composed principally of macrophages and neutrophils infiltrating the dermis (Fig. 2A) and panniculus (Fig. 2B). Additionally, tissue sections were stained with periodic acid schiff (PAS), hematoxylin and eosin, and FITE's (acid-fast) to rule out fungal and mycobacterial infection. However, no microorganisms were detected. Therefore, the dog was definitively diagnosed with SNP based on the clinical and histopathological findings as well as the negative results from the special stainings.

Immunosuppressive treatment with prednisolone (2 mg/kg, PO, twice daily; Solondo, Yuhan, Korea) and cyclosporine (5 mg/kg, PO, once daily; Cypol-N, Chongkundang, Korea) was initiated. The ulcerative skin lesions began to gradually improve 10 days after the initiation of therapy. Because the skin lesions were nearly resolved

after 113 days of therapy (Fig. 1B), the immunosuppressive drugs were discontinued after an additional 21 days of therapy. However, the erythematous nodules and crusts recurred on the trunk, dorsum, and neck 28 days after ceasing treatment (Fig. 1C). To prevent hepatotoxicity caused by continued steroid use, the dog was treated with dapsone (1 mg/kg, PO, twice daily; Dapsone, Taiguk, Korea) for 6 days. Therapy with prednisolone and cyclosporine was then restarted due to a poor response to dapsone (Fig. 1D). There was no recurrence of the skin lesions at the 10 week follow-up appointment (Fig. 1E).

A 9-year-old, intact male, Shih-Tzu dog was referred to the VMC with a history of recurrent skin lesions, such as papules and nodules, over a period of 5 years. A nodule in the right gluteal region ruptured 3 days prior to presentation.

On presentation, multiple skin lesions were palpated over the entire body. The skin lesions were comprised of erythematous, painful, and ruptured nodules on the




Fig. 2. Histopathologic features of skin biopsies obtained from the trunk in case 1. Severe hyperplasia and hypertrophy were observed in the dermis and panniculus adiposus (H&E, $\times 400$). Inflammatory cells composed of neutrophils and macrophages infiltrated the dermis (A) and subcutis (B) (H&E, $\times 200$).




Fig. 3. Histopathologic features of skin biopsies obtained from ruptured nodules on the dorsum and gluteal region in case 2. (A) Diffuse pyogranulomatous dermatitis characterized by intense cellular infiltration of the subcutis (H&E, $\times 100$). (B) The predominant inflammatory cells consisted of neutrophils, histiocytes, and fibrocytes (H&E, $\times 400$).

dorsum, gluteal region, and front feet. Results of the complete blood cell count were within the reference intervals. The serum chemistry panel demonstrated mildly increased ALP level (324 IU/L, reference range: 29-97 IU/L), and the remainder of the values were within the reference intervals.

Impression smears obtained from the ruptured lesions revealed numerous neutrophils, macrophages, red blood cells, and a few eosinophils. Fine needle aspiration of a nodule in the gluteal region showed inflammatory cell infiltrates including degenerate neutrophils and macrophages. Radiographs did not reveal bone involvement or the presence of a foreign body. No etiological agents were observed on the clear taping, trichogram, skin scraping, and cultures for bacteria and fungi.

Skin biopsies were obtained from the nodular lesions on the dorsum and gluteal region. The histopathologic results demonstrated diffuse pyogranulomatous dermatitis (Fig. 3). Cellular infiltrates were observed in the subcutis. The predominant inflammatory cells were neutrophils, histiocytes, and fibrocytes, while microorganisms were not observed. Additionally, tests with special stainings including PAS, hematoxylin and eosin, and FITE did not reveal any microorganisms. Therefore, the dog was definitively diagnosed with SNP based on clinical and histopathological findings.

Initially, an immunomodulatory dose of prednisolone (1 mg/kg, PO, twice daily; Solondo, Yuhan, Korea) was administered. The skin lesions gradually improved, and the prednisolone dose was tapered to 0.25 mg/kg, twice daily

after 56 days of therapy. The prednisolone dose then had to be increased (to 0.5-0.75 mg/kg, PO, twice daily) for an additional 50 days due to recurrence of the lesions. When the dog was examined 106 days after initiation of therapy, the skin lesions remained (Fig. 4A). Because of the low efficacy of prednisolone in this case, the prescription was changed to triamcinolone (0.4 mg/kg, PO, once daily; Tracinon, Chodang, Korea) plus azathioprine (2 mg/kg, PO, once daily; Immuthera, Celltrion, Korea). Five days later, severely elevated levels of ALP (29,100 IU/L, reference range: 29-97 IU/L) and aspartate aminotransferase (142 IU/L, reference range: 21-102 IU/L) were noted. Treatment was changed to dapsone (1 mg/kg, PO, three times a day; Dapsone, Taiguk, Korea) due to presumed steroid-induced hepatotoxicity. The skin lesions improved with the introduction of dapsone (Fig. 4B) so it was continued for another 44 days. There was no evidence of recurrence of SNP 5 months after cessation of treatment with dapsone (Fig. 4C).

Discussion

Because the etiology and pathology of SNP remains unknown, definitive diagnosis of the disease is difficult. Therefore, a diagnosis of SNP should be made only after ruling out all possible infectious or other noninfectious causes by utilizing a multidisciplinary diagnostic approach [1, 14, 15]. Generally, a definitive diagnosis of SNP is based on history, clinical appearance, histopathologic features, the absence of microbiological infection, and the absence of other identifiable causes such




Fig. 4. Temporal changes of skin lesions following immunosuppressive therapy in case 2. (A) Ulcerative and crusted lesions remained 106 days after the initiation of therapy with prednisolone. (B) The cutaneous lesions were greatly improved 27 days after the addition of dapsone. (C) There was no evidence of recurrence 5 months after cessation of dapsone treatment.

as trauma, foreign body, insect bite, and drug eruption. Systemic symptoms including pyrexia, lethargy, and anorexia must also be present [2, 7, 15, 16]. In the present two cases, the possibility of microbiological infection was ruled out based on basic dermatological examination results and non-detection of microorganisms in cultures and special staining tests. Both dogs had systemic signs, such as pyrexia, lethargy, and anorexia. A histopathological analysis demonstrated diffuse pyogranulomatous dermatitis. Therefore, the two dogs were definitively diagnosed with SNP based on clinical and histopathological findings.

In the management of SNP with multiple lesions, treatment with immunosuppressive drugs is commonly used [2, 14]. SNP should be managed with immunosuppressive therapy until achieving remission of clinical signs [6]. Antibiotics should be used to reduce inflammation and drainage when secondary bacterial infections are present [6]. There are reports that describe the synergistic effects of tetracycline and niacinamide used in combination [17]. Though their mechanism of action is unknown, it has been demonstrated that this combination is able to inhibit lymphoblast formation and chemotaxis of neutrophils and eosinophils [18].

In the present two cases, dapsone was prescribed in lieu of steroids due to the presence of presumed steroid-induced hepatotoxicity. Generally, dapsone has the dual function of antimicrobial/antiprotozoal and anti-inflammatory activities. Because the latter capabilities resemble those of non-steroidal anti-inflammatory drugs, dapsone could also be useful in treating chronic inflammatory diseases. Additionally, because of its ability to inhibit leukocytes, it may be useful in the management of immune-mediated dermatoses, such as pemphigus complex, vasculitis, and neutrophilic dermatitis [7, 19].

Although both of the cases in this report were diagnosed with SNP, their clinical response to dapsone was opposite. In the first case, combination therapy with prednisolone and cyclosporine was useful in attenuating the ulcerative lesions, while dapsone alone was not effective in managing the clinical signs. In contrast, in the second case, the therapeutic response to common immunomodulatory drugs, such as prednisolone, triamcinolone, and azathioprine was inadequate. Interestingly, dapsone alone was effective in controlling the clinical signs without causing undue side effects. Generally, dapsone is used for the treatment of immune-mediated dermatoses of mild to moderate severity [2]. Because the skin lesions in the second case were relatively mild in comparison to those in the first case, dapsone may have been more effective in managing the clinical signs observed in the second case.

In conclusion, this report describes the therapeutic effects of dapsone in two dogs with SNP. For the treatment of SNP, current guidelines recommend combination therapy with oral glucocorticoids (prednisolone) and calcineurin inhibitors (cyclosporine) rather than monotherapy

[20]. If patients require long-term therapy to remain in remission, drugs alternative to glucocorticoids are advisable. Because the therapeutic responses and side effects vary with each case, it is important that appropriate drugs are selected with a case-specific approach. Although the usefulness of dapsone in the management of canine SNP is yet unknown, it may be considered in cases of mild to moderate SNP when the use of steroids is not recommended due to its low efficacy or side effects.

Acknowledgements

This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT & Future Planning (NRF-2014R1A1A1036387).

ORCID

Byeong-Teck Kang, <http://orcid.org/0000-0002-4471-4342>

References

1. Contreary CL, Outerbridge CA, Affolter VK, Kass PH, White SD. Canine sterile nodular panniculitis: a retrospective study of 39 dogs. *Vet Dermatol* 2015;26:451-458.
2. Miller WH, Griffin CE, Campbell KL. Miscellaneous skin diseases. In: Miller WH, Griffin CE, Campbell KL (eds.). *Muller and Kirk's small animal dermatology*. 7th ed. St. Louis: Elsevier; 2013. p. 695-723.
3. Gross TL, Ihrke PJ, Walder EJ, Affolter VK. Diseases of the panniculus. In: Gross TL, Ihrke PJ, Walder EJ, Affolter VK. (eds.). *Skin diseases of the dog and cat: clinical and histopathological diagnosis*. 2nd ed. Oxford: Blackwell; 2005. p. 537-558.
4. Neuber A. Panniculitis in dogs and cats. *Companion Animal* 2011;16:27-30.
5. O'Kell AL, Inteeworn N, Diaz SF, Saunders GK, Panciera DL. Canine sterile nodular panniculitis: a retrospective study of 14 cases. *J Vet Intern Med* 2010;24:278-284.
6. Oliveira AM, Obwolo MJ, van den Broek AH, Thoday KL. Focal metatarsal sinus tracts in a Weimaraner successfully managed with ciclosporin. *J Small Anim Pract* 2007;48:161-164.
7. Wozel G, Blasum C. Dapsone in dermatology and beyond. *Arch Dermatol Res* 2014;306:103-124.
8. Gürcan HM, Ahmed AR. Efficacy of dapsone in the treatment of pemphigus and pemphigoid: analysis of current data. *Am J Clin Dermatol* 2009;10:383-396.

9. Hirata Y, Abe R, Kikuchi K, Hamasaka A, Shinkuma S, Ujiie H, Nomura T, Nishie W, Arita K, Shimizu H. Intraepidermal neutrophilic IgA pemphigus successfully treated with dapsone. *Eur J Dermatol* 2012;22:282-283.
10. Goeser MR, Laniosz V, Wetter DA. A practical approach to the diagnosis, evaluation, and management of cutaneous small-vessel vasculitis. *Am J Clin Dermatol* 2014;15:299-306.
11. Yamamoto T, Hoshi M. The dramatic effect of dapsone on cutaneous bullous and pustular rheumatoid vasculitis on the sole. *Int J Rheum Dis* 2015;18:480-481.
12. Cohen PR. Neutrophilic dermatoses: a review of current treatment options. *Am J Clin Dermatol* 2009;10:301-312.
13. Fett N, Kovarik C, Bennett D. Palisaded neutrophilic granulomatous dermatitis without a definable underlying disorder treated with dapsone. *J Am Acad Dermatol* 2011;65:e92-93.
14. Torres SM. Sterile nodular dermatitis in dogs. *Vet Clin North Am Small Anim Pract* 1999;29:1311-1323.
15. Yamagishi C, Momoi Y, Kobayashi T, Ide K, Ohno K, Tsujimoto H, Iwasaki T. A retrospective study and gene analysis of canine sterile panniculitis. *J Vet Med Sci* 2007;69:915-924.
16. Dandrieux JR, Timm K, Roosje PJ, Welle M, Howard J, Brühshwein A, Francey T. Unusual systemic signs in a dog with sterile neutrophilic-macrophagic lymphadenitis and nodular panniculitis. *J Am Anim Hosp Assoc* 2011;47:117-121.
17. Rothstein E, Scott DW, Riis RC. Tetracycline and niacinamide for the treatment of sterile pyogranuloma/granuloma syndrome in a dog. *J Am Anim Hosp Assoc* 1997;33:540-543.
18. Kim HJ, Kang MH, Kim JH, Kim D, Park HM. Sterile panniculitis in dogs: new diagnostic findings and alternative treatments. *Vet Dermatol* 2011;22:352-359.
19. Zhu YI, Stiller MJ. Dapsone and sulfones in dermatology: overview and update. *J Am Acad Dermatol* 2001;45:420-434.
20. Kano R, Okabayashi K, Nakamura Y, Fujiwara K, Hasegawa A, Sasaki Y. Systemic treatment of sterile panniculitis with tacrolimus and prednisolone in dogs. *J Vet Med Sci* 2006;68:95-96.